SG11201701012SA - Anti-vegfr2 antibody therapy for hepatocellular carcinoma - Google Patents
Anti-vegfr2 antibody therapy for hepatocellular carcinomaInfo
- Publication number
- SG11201701012SA SG11201701012SA SG11201701012SA SG11201701012SA SG11201701012SA SG 11201701012S A SG11201701012S A SG 11201701012SA SG 11201701012S A SG11201701012S A SG 11201701012SA SG 11201701012S A SG11201701012S A SG 11201701012SA SG 11201701012S A SG11201701012S A SG 11201701012SA
- Authority
- SG
- Singapore
- Prior art keywords
- hepatocellular carcinoma
- antibody therapy
- vegfr2 antibody
- vegfr2
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037848P | 2014-08-15 | 2014-08-15 | |
| PCT/US2015/044632 WO2016025464A1 (en) | 2014-08-15 | 2015-08-11 | Anti-vegfr2 antibody therapy for hepatocellular carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701012SA true SG11201701012SA (en) | 2017-03-30 |
Family
ID=54007983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701012SA SG11201701012SA (en) | 2014-08-15 | 2015-08-11 | Anti-vegfr2 antibody therapy for hepatocellular carcinoma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10766961B2 (en) |
| EP (1) | EP3180025B1 (en) |
| JP (1) | JP6351828B2 (en) |
| KR (1) | KR20170023414A (en) |
| AP (1) | AP2017009742A0 (en) |
| AU (1) | AU2015301843A1 (en) |
| BR (1) | BR112017001146A2 (en) |
| CA (1) | CA2953576A1 (en) |
| EA (1) | EA201790093A1 (en) |
| ES (1) | ES2777501T3 (en) |
| IL (1) | IL249653A0 (en) |
| MX (1) | MX2017002047A (en) |
| SG (1) | SG11201701012SA (en) |
| TW (1) | TWI569808B (en) |
| WO (1) | WO2016025464A1 (en) |
| ZA (1) | ZA201701548B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195090A1 (en) * | 2018-04-06 | 2019-10-10 | Eli Lilly And Company | Ramucirumab for the treatment of cancers in pediatric patients |
| CN113480653B (en) * | 2021-08-06 | 2022-05-06 | 朱有建 | Application of pharmaceutical composition containing gamma delta T cells in treating cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2478169C (en) | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
| US20120214830A1 (en) * | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
-
2015
- 2015-07-29 TW TW104124594A patent/TWI569808B/en not_active IP Right Cessation
- 2015-08-11 CA CA2953576A patent/CA2953576A1/en not_active Abandoned
- 2015-08-11 ES ES15754347T patent/ES2777501T3/en active Active
- 2015-08-11 SG SG11201701012SA patent/SG11201701012SA/en unknown
- 2015-08-11 KR KR1020177003774A patent/KR20170023414A/en active Search and Examination
- 2015-08-11 MX MX2017002047A patent/MX2017002047A/en unknown
- 2015-08-11 EP EP15754347.1A patent/EP3180025B1/en active Active
- 2015-08-11 BR BR112017001146A patent/BR112017001146A2/en not_active Application Discontinuation
- 2015-08-11 EA EA201790093A patent/EA201790093A1/en unknown
- 2015-08-11 WO PCT/US2015/044632 patent/WO2016025464A1/en active Application Filing
- 2015-08-11 US US15/501,507 patent/US10766961B2/en active Active
- 2015-08-11 AP AP2017009742A patent/AP2017009742A0/en unknown
- 2015-08-11 AU AU2015301843A patent/AU2015301843A1/en not_active Abandoned
- 2015-08-11 JP JP2017508483A patent/JP6351828B2/en active Active
-
2016
- 2016-12-19 IL IL249653A patent/IL249653A0/en unknown
-
2017
- 2017-03-02 ZA ZA2017/01548A patent/ZA201701548B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6351828B2 (en) | 2018-07-04 |
| TW201617094A (en) | 2016-05-16 |
| IL249653A0 (en) | 2017-02-28 |
| EA201790093A1 (en) | 2017-06-30 |
| MX2017002047A (en) | 2017-05-25 |
| JP2017528445A (en) | 2017-09-28 |
| EP3180025B1 (en) | 2020-02-26 |
| AP2017009742A0 (en) | 2017-02-28 |
| US10766961B2 (en) | 2020-09-08 |
| TWI569808B (en) | 2017-02-11 |
| ES2777501T3 (en) | 2020-08-05 |
| KR20170023414A (en) | 2017-03-03 |
| WO2016025464A1 (en) | 2016-02-18 |
| BR112017001146A2 (en) | 2017-11-14 |
| CA2953576A1 (en) | 2016-02-18 |
| US20170226212A1 (en) | 2017-08-10 |
| EP3180025A1 (en) | 2017-06-21 |
| ZA201701548B (en) | 2018-12-19 |
| AU2015301843A1 (en) | 2017-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272572B (en) | Antibody compositions for tumor treatment | |
| IL250672A0 (en) | Treatment regimens using anti-nkg2a antibodies | |
| AP2017009765A0 (en) | Anti-tigit antibodies | |
| HK1245804A1 (en) | Anti-csf1r antibodies for treating pvns | |
| IL273265A (en) | Novel combinations for antigen based therapy | |
| EP3107538A4 (en) | Combination therapy for hepatocellular carcinoma | |
| IL247988A0 (en) | Antibodies against hpa-1a | |
| ZA201701548B (en) | Anti-vegfr2 antibody therapy for hepatocellular carcinoma | |
| GB201419089D0 (en) | Anti-TIM-3 antibodies | |
| GB201419092D0 (en) | Anti-TIM-3 antibodies | |
| GB201417614D0 (en) | Antibodies | |
| GB201414270D0 (en) | Antibodies | |
| GB201405775D0 (en) | Antibodies | |
| GB201401200D0 (en) | Antibodies |